Geruso Michael, Layton Timothy, Prinz Daniel
Department of Economics, University of Texas at Austin, 2225 Speedway, Austin, TX 78712, and NBER.
Department of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, MA 02115, and NBER.
Am Econ J Econ Policy. 2019 May;11(2):64-107. doi: 10.1257/pol.20170014.
We study insurers' use of prescription drug formularies to screen consumers in the ACA Health Insurance exchanges. We begin by showing that exchange risk adjustment and reinsurance succeed in neutralizing selection incentives for most, but not all, consumer types. A minority of consumers, identifiable by demand for particular classes of prescription drugs, are predictably unprofitable. We then show that contract features relating to these drugs are distorted in a manner consistent with multidimensional screening. The empirical findings support a long theoretical literature examining how insurance contracts offered in equilibrium can fail to optimally trade off risk protection and moral hazard.
我们研究了保险公司在《平价医疗法案》(ACA)医疗保险交易所中利用处方药处方集来筛选消费者的情况。我们首先表明,交易所的风险调整和再保险成功地消除了大多数(但不是所有)消费者类型的选择激励。少数因对特定类别的处方药有需求而可识别的消费者,预计是无利可图的。然后我们表明,与这些药物相关的合同特征以与多维筛选一致的方式被扭曲。实证结果支持了长期以来的理论文献,该文献探讨了均衡状态下提供的保险合同如何无法在风险保护和道德风险之间进行最优权衡。